{"nctId":"NCT00692913","briefTitle":"A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)","startDateStruct":{"date":"2008-06"},"conditions":["Osteoporosis"],"count":515,"armGroups":[{"label":"FOSAVANCE 5600","type":"EXPERIMENTAL","interventionNames":["Drug: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)","Dietary Supplement: Calcium Supplement 500 mg"]},{"label":"Referred-Care Model","type":"OTHER","interventionNames":["Other: Referred-Care Model"]}],"interventions":[{"name":"FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)","otherNames":[]},{"name":"Calcium Supplement 500 mg","otherNames":[]},{"name":"Referred-Care Model","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Female\n* 65 years or older\n* Diagnosed with osteoporosis (Bone Mineral Density (BMD) T-score \\<= -2.5 at spine or hip) or prior fragility fracture BMD T-score \\<=-1.5 in at least one of the anatomic sites including lumbar spine, total hip, and femoral neck sites\n* Postmenopausal\n* Low levels of vitamin D as measured 25-hydroxyvitamin D\n* Has fallen at least once within the past 12 months\n\nExclusion Criteria:\n\n* Unable to stand or sit upright for at least 30 minutes\n* Has a bone disorder other than osteoporosis\n* Contraindication to the use of FOSAVANCE","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26","description":"Percentage of participants with serum levels of 25-hydroxyvitamin D below\n\n20 nanograms/milliliter (ng/mL) after 26 weeks of treatment with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","spread":null},{"groupId":"OG001","value":"31.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline at Week 26 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio","description":"N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio (NTx) is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: \\[100 \\* ((Week 26/Baseline)-1)\\]. The greater the percent decrease from baseline, the greater the response to therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-57.06","spread":null},{"groupId":"OG001","value":"-47.36","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline at Week 26 in Bone-Specific Alkaline Phosphatase","description":"Bone-Specific Alkaline Phosphatase (BSAP) is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: \\[100 \\* ((Week 26/Baseline)-1)\\]. The greater the percent decrease from baseline, the greater the response to therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.67","spread":null},{"groupId":"OG001","value":"-39.60","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 52","description":"Percentage of participants with serum levels of 25-hydroxyvitamin D below\n\n20 ng/mL after 52 weeks of treatment (6 month extension study) with FOSAVANCE 5600 once weekly versus Referred-Care in postmenopausal women with osteoporosis and at increased risk of falls.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"36.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine and Total Hip Bone Mineral Density","description":"Bone Mineral Density (BMD) as measured by Dual Energy X-Ray Absorptiometry (DEXA) and measured in g/cm\\^2 was obtained at baseline (visit 1) and Week 52 (visit 13) or at early study discontinuation visit. The percent change was calculated as: \\[100 \\* ((Week 52/Baseline)-1)\\]. The greater the percent change from baseline, the greater the response to therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.92","spread":null},{"groupId":"OG001","value":"3.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":null},{"groupId":"OG001","value":"1.40","spread":null}]}]}]},{"type":"SECONDARY","title":"Falls Per Participant","description":"Number of falls per participant was measured.\n\nThe fall event rate during the study period was defined as the number of adjudicated falls during the study period divided by the total patient-years in the study. Each participant was to be in the study for approximately one year.\n\nIn order to guide and standardize all procedures during the fall adjudication process, a Standard Operating Procedure for Fall Adjudication was created by the\n\nSPONSOR and served as a guideline to standardize operational procedures for fall adjudication.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.51","spread":"1.53"},{"groupId":"OG001","value":"0.45","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline at Week 52 in N-Telopeptides of Type 1 Collagen to Urine Creatinine Ratio","description":"NTx is a urine biochemical marker of bone resorption and measured in nanomoles (nmol) Bone Collagen Equivalents (BCE)/millimoles (mmol) creatinine. The percent change was calculated as: \\[100 \\* ((Week 52/Baseline)-1)\\]. The greater the percent decrease from baseline, the greater the response to therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-58.42","spread":null},{"groupId":"OG001","value":"-50.07","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline at Week 52 in Bone-Specific Alkaline Phosphatase","description":"BSAP is a serum biochemical marker of bone formation and measured in micrograms/Liter (mcg/L). The percent change was calculated as: \\[100 \\* ((Week 52/Baseline)-1)\\]. The greater the percent decrease from baseline, the greater the response to therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-51.21","spread":null},{"groupId":"OG001","value":"-43.13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":25,"n":254},"commonTop":["Arthralgia","Back Pain","Contusion","Urinary Tract Infection","Dizziness"]}}}